Directorio

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.

After the screening, the study will last up to one year and has two parts. People in the study will be randomly placed into two groups. In Part A, one group will get the study medicine, and the other group will get a placebo, which looks like the medicine but does not do anything. In Part B, everyone will get the study medicine. The medicine or placebo will be given through a tube into a vein in the arm. During the study, everyone will have checkups, give blood samples, have kidney tissue samples taken (called biopsies), and answer questions about how they feel.

We are doing this study to find the most effective, safe dose of an experimental drug called FG-3246 (the study drug) that is being developed for people with metastatic castration-resistant prostate cancer. We want to know if it is able to shrink the size of tumors and delay the progression of the disease.

We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.

People in this study will receive medicines to help prevent infections after a kidney transplant. They will be placed into one of two groups by chance. One group will receive a study medicine called frexalimab, while the other group will receive tacrolimus, a standard anti rejection medicine. Frexalimab is given right after the transplant, then again two weeks later, four weeks later, and every four weeks after that for up to five years. Participants will have regular blood tests, urine tests, physical exams, heart tests, questionnaires, and kidney biopsies to monitor their health and the transplanted kidney. Some activities, such as interviews and physical activity tracking, are optional. Researchers want to learn if frexalimab is a safe and effective alternative to tacrolimus for preventing kidney transplant rejection.

If you join the study, you will sign a consent form, complete a questionnaire, and provide a blood sample. You will also have your regular low-dose CT scan for lung cancer screening as part of your usual medical care. The study team will review your medical records and follow your health for about 2 years.